TY - JOUR
T1 - Grippenet
T2 - A new tool for the monitoring, risk-factor and vaccination coverage analysis of influenza-like illness in switzerland
AU - Richard, Aude
AU - Müller, Laura
AU - Wisniak, Ania
AU - Thiabaud, Amaury
AU - Merle, Thibaut
AU - Dietrich, Damien
AU - Paolotti, Daniela
AU - Jeannot, Emilien
AU - Flahault, Antoine
N1 - Funding Information:
Funding: Aude Richard’s position at the University of Geneva was funded by the Health Promotion Switzerland foundation during the writing of this article. This research received no other external funding.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/9
Y1 - 2020/9
N2 - Implemented in Switzerland in November 2016, Grippenet provides Internet-based participatory surveillance of influenza-like illness (ILI). The aim of this research is to test the feasibility of such a system and its ability to detect risk factors and to assess ILI-related behaviors. Participants filled in a web-based socio-demographic and behavioral questionnaire upon registration, and a weekly symptoms survey during the influenza season. ILI incidence was calculated weekly, and risk factors associated to ILI were analyzed at the end of each season. From November 2016 to May 2019, 1247 participants were included. The crossing of the Sentinel System (Sentinella) epidemic threshold was associated with an increase or decrease of Grippenet ILI incidence, within the same week or earlier. The number of active users varied according to ILI incidence. Factors associated with ILI were: ages 0–4 compared with 5–14 (adjusted odds ratio (AOR) 0.6, 95% confidence interval (CI) 0.19–0.99), 15–29 (AOR 0.29, 95% CI 0.15–0.60), and 65+ (AOR 0.38, 95% CI 0.16–0.93); female sex (male AOR 0.81, 95% CI 0.7–0.95); respiratory allergies (AOR 1.58, 95% CI 1.38–1.96), not being vaccinated (AOR 2.4, 95% CI 1.9–3.04); and self-employment (AOR 1.97, 95% CI 1.33–3.03). Vaccination rates were higher than those of the general population but not high enough to meet the Swiss recommendations. Approximately, 36.2% to 42.5% of users who reported one or more ILIs did not seek medical attention. These results illustrate the potential of Grippenet in complementing Sentinella for ILI monitoring in Switzerland.
AB - Implemented in Switzerland in November 2016, Grippenet provides Internet-based participatory surveillance of influenza-like illness (ILI). The aim of this research is to test the feasibility of such a system and its ability to detect risk factors and to assess ILI-related behaviors. Participants filled in a web-based socio-demographic and behavioral questionnaire upon registration, and a weekly symptoms survey during the influenza season. ILI incidence was calculated weekly, and risk factors associated to ILI were analyzed at the end of each season. From November 2016 to May 2019, 1247 participants were included. The crossing of the Sentinel System (Sentinella) epidemic threshold was associated with an increase or decrease of Grippenet ILI incidence, within the same week or earlier. The number of active users varied according to ILI incidence. Factors associated with ILI were: ages 0–4 compared with 5–14 (adjusted odds ratio (AOR) 0.6, 95% confidence interval (CI) 0.19–0.99), 15–29 (AOR 0.29, 95% CI 0.15–0.60), and 65+ (AOR 0.38, 95% CI 0.16–0.93); female sex (male AOR 0.81, 95% CI 0.7–0.95); respiratory allergies (AOR 1.58, 95% CI 1.38–1.96), not being vaccinated (AOR 2.4, 95% CI 1.9–3.04); and self-employment (AOR 1.97, 95% CI 1.33–3.03). Vaccination rates were higher than those of the general population but not high enough to meet the Swiss recommendations. Approximately, 36.2% to 42.5% of users who reported one or more ILIs did not seek medical attention. These results illustrate the potential of Grippenet in complementing Sentinella for ILI monitoring in Switzerland.
KW - Influenza
KW - Influenza-like illness
KW - Participatory surveillance
KW - Syndromic surveillance
UR - http://www.scopus.com/inward/record.url?scp=85087164467&partnerID=8YFLogxK
UR - https://www.ncbi.nlm.nih.gov/pubmed/32605076
U2 - 10.3390/vaccines8030343
DO - 10.3390/vaccines8030343
M3 - Article
C2 - 32605076
AN - SCOPUS:85087164467
SN - 2076-393X
VL - 8
SP - 1
EP - 19
JO - Vaccines
JF - Vaccines
IS - 3
M1 - 343
ER -